181 related articles for article (PubMed ID: 16869822)
1. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
Balakrishnan K; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
[TBL] [Abstract][Full Text] [Related]
2. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
3. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
Chui J; Tordoff J; Kennedy J; Reith D
Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
[TBL] [Abstract][Full Text] [Related]
4. Effect of the pediatric exclusivity provision on children's access to medicines.
Grieve J; Tordoff J; Reith D; Norris P
Br J Clin Pharmacol; 2005 Jun; 59(6):730-5. PubMed ID: 15948940
[TBL] [Abstract][Full Text] [Related]
5. Access to prescribing information for paediatric medicines in the USA: post-modernization.
Young L; Lawes F; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2009 Mar; 67(3):341-6. PubMed ID: 19220278
[TBL] [Abstract][Full Text] [Related]
6. The licensing of medicines in the UK.
Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
[TBL] [Abstract][Full Text] [Related]
7. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
8. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
[TBL] [Abstract][Full Text] [Related]
9. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
10. The medicines for children agenda in the UK.
Stephenson T
Br J Clin Pharmacol; 2006 Jun; 61(6):716-9. PubMed ID: 16722834
[TBL] [Abstract][Full Text] [Related]
11. The availability and age-appropriateness of medicines authorized for children in The Netherlands.
van Riet-Nales DA; de Jager KE; Schobben AF; Egberts TC; Rademaker CM
Br J Clin Pharmacol; 2011 Sep; 72(3):465-73. PubMed ID: 21477143
[TBL] [Abstract][Full Text] [Related]
12. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
Ragupathy R; Tordoff J; Norris P; Reith D
Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
[TBL] [Abstract][Full Text] [Related]
13. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
14. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study.
Venables R; Batchelor H; Stirling H; Marriott J
Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666
[TBL] [Abstract][Full Text] [Related]
15. Availability of pediatric-evaluated formulations in Serbia.
Božić B; Stupar S; Stupar D; Babić U; Bajčetić M
Indian J Pharmacol; 2017; 49(2):189-193. PubMed ID: 28706333
[TBL] [Abstract][Full Text] [Related]
16. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
17. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
Riedel C; Lehmann B; Broich K; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
[TBL] [Abstract][Full Text] [Related]
18. European perspectives on pediatric formulations.
Breitkreutz J
Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
[TBL] [Abstract][Full Text] [Related]
19. Paediatric off-label and unlicensed prescribing in primary care in Malta: Prospective observational drug utilisation study.
Ellul IC; Grech V; Attard-Montalto S
Int J Risk Saf Med; 2015; 27(3):123-34. PubMed ID: 26410246
[TBL] [Abstract][Full Text] [Related]
20. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
